The share of the Spanish pharmaceutical company Almirall jumped 11% as the company set optimistic targets for the year, despite the massive decline in the value of Seysara acne treatment, which led its results for 2021 “in the red”.
The company announced EBITDA from core activities of 211 million Euros, increased by 17% compared to the previous year, achieving the target for the end of 2021, at approximately 200-215 million Euros.
However, Almirall, which specializes in dermatological treatments, showed net results of losses of 40.9 million Euros in 2021 due to impairments of 103 million Euros, including an impairment of the value of Seysara, which had already announced results. semester last July.
Almirall’s target for EBITDA for the year is set at 190-210 million Euros, which is higher than that of Credit Suisse, the investment bank stressed, adding that it forecasts strong cash flows in 2022.
Almirall revenue rose 2.7% in 2021 to € 836.5 million, but US sales fell 7.9% due to competition from generic drugs.
Source: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
